Stock YBGJ YUBO INTERNATIONAL BIOTECH LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Yubo International Biotech Limited

Equities

YBGJ

US9883661004

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 10:51:53 2024-04-30 am EDT 		5-day change 1st Jan Change
0.3487 USD +39.54% Intraday chart for Yubo International Biotech Limited +66.05% +16.23%
Apr. 12 Yubo International Biotech Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Yubo International Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 49.28 11.38 35.95
Enterprise Value (EV) 1 51.94 12.16 36.33
P/E ratio -31.9 x -9.36 x -30.1 x
Yield - - -
Capitalization / Revenue 39,599,158 x 109,154,656 x 59,447,104 x
EV / Revenue 41,741,978 x 116,560,264 x 60,084,725 x
EV / EBITDA -34.1 x -10.3 x -36.2 x
EV / FCF -54,689,651 x -33,076,781 x 80,445,030 x
FCF Yield -0% -0% 0%
Price to Book -376 x -20.1 x -19.5 x
Nbr of stocks (in thousands) 118,182 119,821 119,821
Reference price 2 0.4170 0.0950 0.3000
Announcement Date 4/15/22 4/14/23 4/12/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales - 1.354 1.244 0.1043 0.6047
EBITDA 1 -0.231 -0.6987 -1.521 -1.178 -1.005
EBIT 1 -0.2311 -0.7118 -1.543 -1.205 -1.195
Operating Margin - -52.58% -123.99% -1,155.72% -197.58%
Earnings before Tax (EBT) 1 -0.2312 -0.7118 -1.542 -1.205 -1.195
Net income 1 -0.2312 -0.7118 -1.542 -1.205 -1.195
Net margin - -52.58% -123.95% -1,155.5% -197.64%
EPS 2 -0.0231 -0.0708 -0.0131 -0.0101 -0.009973
Free Cash Flow - 0.274 -0.9498 -0.3675 0.4516
FCF margin - 20.24% -76.33% -352.39% 74.69%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 1/14/21 4/19/21 4/15/22 4/14/23 4/12/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 0.55 - 2.67 0.77 0.39
Net Cash position 1 - 1.07 - - -
Leverage (Debt/EBITDA) -2.36 x - -1.753 x -0.6558 x -0.3838 x
Free Cash Flow - 0.27 -0.95 -0.37 0.45
ROE (net income / shareholders' equity) - -85.9% -298% 346% 99.2%
ROA (Net income/ Total Assets) - -24.9% -27.4% -21.7% -37.2%
Assets 1 - 2.859 5.624 5.548 3.214
Book Value Per Share 2 0.0500 0.1200 -0 -0 -0.0200
Cash Flow per Share 2 0 0.1400 0 0 0
Capex 1 0.04 0.04 0.56 - -
Capex / Sales - 3.14% 45.38% - -
Announcement Date 1/14/21 4/19/21 4/15/22 4/14/23 4/12/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
YUBO INTERNATIONAL BIOTECH LIMITED Stock Yubo International Biotech Limited
+16.23% 41.78M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.17% 42.19B
MODERNA, INC. Stock Moderna, Inc.
+10.92% 42.24B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.15B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.23% 24.63B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.79% 18.2B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.69% 12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.13% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.57% 10.4B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. YBGJ Stock
  4. Financials Yubo International Biotech Limited